美国联邦医疗法官起诉CMS, MMJ sues CMS over hemp program allowing unregulated products.

美国联邦医疗保险和医疗补助中心 (Center for Medicare & Medicaid Services) 的新计划允许提供商提供大麻衍生类大麻产品,其中多达0.3%的delta-9THC. MMJ国际控股公司于4月份提起联邦诉讼阻止该项目的实施. MMJ International Holdings filed a federal lawsuit in April to block the Centers for Medicare & Medicaid Services' new program allowing providers to offer hemp-derived cannabinoid products with up to 0.3% delta-9 THC. 公司认为该计划绕过了必要的规则制定, 并破坏了FDA药物批准程序, 为不受监管的产品创造联邦通道. The company argues the program bypassed required rulemaking and undermines the FDA's drug approval process, creating a federal pathway for unregulated products. 诉讼人正在寻求暂停该计划的初步禁令, 在华盛顿特区的一个联邦法院审查其合法性. Plaintiffs are seeking a preliminary injunction to halt the program while a federal court in Washington, D.C., reviews its legality.